Zachary J. Williams
M.D./Ph.D. student
Vanderbilt University
From this contributor
Designing autism-friendly trials: Q&A with Caroline Averius and Zachary Williams
The pair’s new guidebook offers practical steps to make clinical trials easier and more meaningful for autistic participants.
Designing autism-friendly trials: Q&A with Caroline Averius and Zachary Williams
A new hub for participatory research: Q&A with Zachary Williams
Last month, the International Society for Autism Research launched the INSAR Community Collaborator Request (ICCR), an online forum to foster collaborations between autistic people and autism researchers. Its creator, Zachary Williams, explains how researchers can make the most of this new resource.
A new hub for participatory research: Q&A with Zachary Williams
Measuring alexithymia in autistic people
Despite the growing interest in alexithymia in autism research, the tools commonly used to measure this trait may not work reliably in autistic populations. A new scoring method fills that gap.
Measuring alexithymia in autistic people
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.